Palmitoylated SCP1 is Targeted to the Plasma Membrane and Negatively Regulates Angiogenesis.
Peng Liao,Weichao Wang,Yu Li,Rui Wang,Jaili Jin,Weijuan Pang,Yunfei Chen,Mingyue Shen,Xinbo Wang,Dongyang Jiang,Jinjiang Pang,Mingyao Liu,Xia Lin,Xin-Hua Feng,Ping Wang,Xin Ge
DOI: https://doi.org/10.7554/elife.22058
IF: 7.7
2017-01-01
eLife
Abstract:SCP1 as a nuclear transcriptional regulator acts globally to silence neuronal genes and to affect the dephosphorylation of RNA Pol ll. However, we report the first finding and description of SCP1 as a plasma membrane-localized protein in various cancer cells using EGFP- or other epitope-fused SCP1. Membrane-located SCP1 dephosphorylates AKT at serine 473, leading to the abolishment of serine 473 phosphorylation that results in suppressed angiogenesis and a decreased risk of tumorigenesis. Consistently, we observed increased AKT phosphorylation and angiogenesis followed by enhanced tumorigenesis in Ctdsp1 (which encodes SCP1) gene - knockout mice. Importantly, we discovered that the membrane localization of SCP1 is crucial for impeding angiogenesis and tumor growth, and this localization depends on palmitoylation of a conserved cysteine motif within its NH2 terminus. Thus, our study discovers a novel mechanism underlying SCP1 shuttling between the plasma membrane and nucleus, which constitutes a unique pathway in transducing AKT signaling that is closely linked to angiogenesis and tumorigenesis.